Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) Book value per share
Bio-Rad Laboratories, Inc.'s book value per share at the end of fiscal 2025 was 273×, up 17.4% from 233× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 284×. Over the past ten years it has ranged from 85.3× (fiscal 2015) to 459× (fiscal 2021); the current reading is higher than 64% of that period. Bio-Rad Laboratories, Inc. ranks 1st of 149 Medical Devices companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 273× | 17.42% |
| FY2024 | 233× | (22.20%) |
| FY2023 | 299× | (7.30%) |
| FY2022 | 323× | (29.63%) |
| FY2021 | 459× | 38.22% |
| FY2020 | 332× | 72.11% |
| FY2019 | 193× | 43.12% |
| FY2018 | 135× | 36.37% |
| FY2017 | 98.8× | 12.79% |
| FY2016 | 87.6× | 2.67% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 284× | 5.85% |
| Jun 2026 | 268× | 5.54% |
| Mar 2026 | 254× | (7.04%) |
| Dec 2025 | 273× | 9.26% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. | 284× |
| BIO Bio-Rad Laboratories, Inc. compare | 284× |
| PEN Penumbra, Inc. compare | 40.2× |
| GMED Globus Medical, Inc. compare | 35.8× |
| PODD Insulet Corporation compare | 22.8× |
| BRKR Bruker Corporation compare | 15.1× |
| GKOS Glaukos Corporation compare | 12.1× |
| TXG 10x Genomics compare | 6.4× |
| SNN Smith & Nephew SNATS, Inc. compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement